Altered intracellular localization of BRK/Sik protein tyrosine kinase in human prostate tumors
AssigneeThe Board of Trustees of the Univeristy of Illinois
InventorsAngela Tyner, Jason J. Derry
Life of this patent
Estimating the term…
Abstract
The invention provides methods for detecting abnormal prostate conditions, such as benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), and adenocarcinoma, in an animal by comparing the amount of the Breast Tumor Kinase (BRK) tyrosine kinase in the nuclei of prostate luminal epithelial cells in a test sample with an amount of nuclear BRK protein in epithelial cells of normal prostate glands.
Claims8
A method of diagnosing an abnormal prostate condition in an animal, wherein the abnormal prostate condition is adenocarcinoma, benign prostatic hyperplasia (BPH), or prostatic intraepithelial neoplasia (PIN), the method comprising the steps of:
- a. assaying a prostate tissue sample from the animal to determine how much Breast Tumor Kinase (BRK) protein is located in nuclei of epithelial cells within the animal prostate tissue;
- b. assaying a normal prostate tissue sample from the animal to determine how much BRK protein is located in the nuclei of epithelial cell within the normal prostate tissue;
- and
- c. comparing the amount of BRK protein in the nuclei of epithelial cells from the prostate tissue sample in step (a) with the amount of BRK protein in the nuclei of epithelial cells from the normal prostate tissue sample in step (b),
- wherein an abnormal prostate having adenocarcinoma, benign prostatic hyperplasia (BPH), or prostatic intraepithelial neoplasia (PIN) is identified if the amount of BRK protein in the nuclei of epithelial cells from step (a) is less than the amount of BRK protein in the nuclei of epithelial cells from step (b).
Dependencies are inferred from the claim text.